Medical treatment of Clostridium difficile-related gastrointestinal infection - whither vancomycin?

MICHAEL WHITBY, CONSULTANT PHYSICIAN INFECTION DIRECTOR OF INFECTIOUS DISEASES, INFECTION CONTROL & SEXUAL HEALTH, PRINCESS ALEXANDRA HOSPITAL, BRISBANE. (REPRINTED WITH PERMISSION OF “INFECTION LINE” WHICH IS SPONSORED BY SMITH KLINE BEECHAM)

One of the major advances in anaerobic microbiology in the past five decades has been clarifying the causal relationship between *Clostridium difficile* and pseudomembranous colitis, and its association with previous antimicrobial therapy. It is now clear that *C. difficile* is responsible for virtually all cases of pseudomembranous colitis and up to 20% of cases of antibiotic-associated diarrhoea. Cindamycin is widely recognised for its propensity to induce these diseases, but broad-spectrum penicillins and cephalosporins (reflecting their widespread usage) are much more common precipitating agents.

With two years of the discovery of *C. difficile* diarrhoea, vancomycin was shown to be an effective therapeutic agent. Increasing knowledge of the pathogenesis of this infection has confirmed oral vancomycin to be ideal in that it destroys *C. difficile* at low concentrations. It is also minimally absorbed, and therefore excreted in high levels in the faeces without significant metabolism. Numerous studies attest to its efficacy at doses of between 0.5 and 2.0 g per day for periods of seven to 14 days, leading to its widespread use in this condition. However, the recent emergency of vancomycin-resistant enterococci (VREs), predominantly in the USA and with an apparent association with widespread use of parenteral and particularly oral vancomycin, has resulted in reconsideration of its place in treatment of *C. difficile*-associated diarrhoea. The US Hospital Infection Control Practices Advisory Committee for Prevention of the Spread of Vancomycin Resistance have discouraged the use of oral vancomycin in therapy for *C. difficile*-associated diarrhoea except for failure of metronidazole or severe potentially life threatening illness.

Although VREs are not yet a problem in Australia, their appearance would herald a significant threat. Vancomycin usage in Australia would be difficult to curtail, given the endemic levels of methicillin-resistant *Staphylococcus aureus* in eastern state hospitals.

The following alternatives exist for the treatment of *C. difficile*-induced diarrhoea.

**DISCONTINUATION OF THE OFFENDING DRUG**

While this is a mandatory step in treatment, the initial question that must always be asked is whether 'specific therapy' is really needed. Most patients run a self-limiting course so that simply ceasing the initiating antibiotic may be sufficient.

**ALTERNATIVE ANTIMICROBIAL AGENTS**

- **Metronidazole**
  - In controlled therapeutic trials metronidazole has been demonstrated effective with doses of 1.0-1.5 g per day in three or four divided doses. It is available in Australia on PBS prescription and remains the most inexpensive treatment for *C. difficile*-associated diarrhoea, with over 95% efficacy and less than 10% relapse rate. However, metronidazole is, theoretically at least, highly absorbed from the upper gastrointestinal tract, unlike vancomycin. This leads to low faecal concentrations which may be even further diminished by the metabolic activity of faecal flora.

- **Bacitracin**
  - Like vancomycin, bacitracin is active against *C. difficile* and is minimally absorbed from the gastrointestinal system. Clinical trials utilising 80-100,000 units per day in four divided doses have shown efficacy of greater than 80%, although with higher relapse rates than either vancomycin or metronidazole. Although cheaper than oral vancomycin, it is not available on PBS prescription in Australia, only on formularies of a number of public hospitals. The disagreeable taste and propensity to induce nausea can be reduced by administering the agent in a capsule.

- **Other antimicrobials**
  - A number of other antibiotics have useful activity against *C. difficile* in both primary and relapsing *C. difficile*-associated diarrhoea, including tetracycline, teicoplanin, fusidic acid and rifampicin. However, a role for these agents in routine practice cannot be recommended due to a number of considerations including the potential development of resistance, cost, availability and so on.

**Parenteral therapy**

It is preferable to treat with an oral agent where possible because of the lower cost, the pharmacokinetics and greater published experience. However, in certain patients unable to tolerate oral medication, parenteral therapy will be indicated.

Metronidazole is drug of choice in this situation as excretion of drug from the inflammed colon results in bactericidal faecal concentration. This is not the case with parenteral vancomycin where faecal levels have proved very poor.

**Anion-exchange resins**

Cholestyramine and, to a lesser extent, colestipol are anion exchange resins which are entirely excreted in the stool, reversibly binding the toxins produced by *C. difficile*. Clinical studies have shown some efficacy when administered alone at 12-16 g in three or four divided doses. As antibiotics and resin act by different mechanisms, it was hoped that the combination would be better than vancomycin alone, although this has not been proved in either clinical or animal studies. Administration of cholestyramine inactivates concurrently administered vancomycin as a result of intraluminal binding and leads to a significant loss of activity of both agents. Where it is felt there may be some advantage in giving both, it seems sensible to utilise maximum doses and to administer the two drugs separately. A routine role for anion exchange resins has not been established, although they may have a place in monotherapy of milder disease or as combination treatment in relapse.

**Modification of colonic flora**

Biotherapy is an alternative and logical approach to treatment of *C. difficile*-associated diarrhoea, given that the disease originates from a change in bowel flora. A number of therapies have been tried with limited success. These included administration of
After 20 years of clinical experience, the optimal treatment of relapses suggests biotherapy with an effective and inexpensive therapy for primary infection.

More recently, the utilization of *Saccharomyces boulardii* appears to show considerable promise. This year, originally isolated from lychees and a close relative of *Saccharomyces cerevisiae*, survives exposure to gastric acid and colonizes the colon so long as daily administration is continued, but is readily cleared when treatment is ceased. Clinical success in the treatment of *C. difficile*-associated diarrhoea has been demonstrated in a number of studies of both primary cases and relapses, either as monotherapy or in combination with a standard antibiotic. However, apart from two double-blind placebo-controlled studies, most evidence supporting its use comes from small open therapeutic trials.

The yeast appears to reduce the pathogenicity of *C. difficile* through a specific mechanism, either by interfering with the production and elaboration of specific toxins or by interfering with the production of specific toxins. Continuing studies are required to ensure that *S. boulardii* treatment does provide a definitive cure and not simply extend a period of symptom-free remission.

### Anti-peristaltic therapy

Anti-peristaltic agents do not reduce the time to resolution of *C. difficile* diarrhoea. General consensus is that they should not be used; there is anecdotal evidence that diphenoxylate (Lomotil) may be deleterious to patients with *C. difficile* diarrhoea and may predispose them to toxic megacolon. In theory, these agents, by slowing motility, might also lead to increased absorption of metronidazole, with lower faecal concentrations and therefore poorer outcomes of treatment.

### Conclusion

After 20 years of clinical experience, specific guidelines for the treatment of *C. difficile* infection of the gastrointestinal tract have evolved. Oral metronidazole, which may be necessary after cessation of the precipitating agent, is now regarded as an effective and inexpensive therapy for primary infection. Bacitracin is an effective alternative. The optimal treatment of relapses remains to be defined but recent research suggests biotherapy with *S. boulardii*, either alone or in combination with antibiotics, may lead to superior outcomes. New and innovative approaches are needed in this common condition, with a protective vaccine remaining a tantalising possibility in the distant future.

### References


